Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: November 16, 2006
Last updated: February 3, 2017
Last verified: February 2017

This study will assess the quality of life in renal transplant recipients who require a reduced dose of mycophenolate mofetil (MMF) because of gastrointestinal (GI) side effects and will also access the relationship between mycophenolic acid (MPA) dose in those patients receiving enteric-coated mycophenolate sodium formulation(EC-MPS).

Patients will be evaluated at baseline, 2 weeks after study medicine conversion and then again at 12 weeks post-conversion.

Condition Intervention Phase
Maintenance Kidney Transplant
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Drug: Mycophenolate mofetil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: A 12-week Multicenter, Randomized, Open Study to Evaluate the Effects of Enteric-coated Mycophenolate Sodium (EC-MPS) in Terms of Quality of Life in Patients With Gastrointestinal (GI) Symptoms Treated With MMF (Mycophenolate Mofetil) After Kidney Transplant.

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To determine the effect of the use of EC-MPS on the quality of life of patients requiring MMF dose reduction due to gastrointestinal symptoms [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • To determine whether EC-MPS enables the administration of higher doses with good tolerability, compared with standard MMF treatment, in patients with shown susceptibility to undesirable GI effects [ Time Frame: 12 weeks ]
  • To measure health-related quality of life (HRQOL) through the GI quality of life index (GIQLI) and the psychological general well-being index (PGWB) [ Time Frame: 12 weeks ]

Enrollment: 136
Study Start Date: July 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EC MPS
Up to 1440mg taken in two doses
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Active Comparator: Mycophenolate mofetil
250 mg or 500 mg in two equal doses
Drug: Mycophenolate mofetil


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Patients who are recipients of a renal transplant.
  2. Patients treated with an immunosuppressive regiment including MMF before recruitment.
  3. Patients suffering from GI side effects related to MMF standard doses or patients treated with a reduced MMF dose to control the aforementioned GI side effects.
  4. Patients 18 years or older.
  5. Patients who have given written informed consent to participate in the study
  6. Patients complying with all study requirements including completing questionnaires and attending to the three study visits.

Exclusion criteria

  1. Patients with GI symptoms assumed or known not to be caused by MPA therapy (eg. oral bisphosphonate induced, infectious diarrhea)
  2. Acute rejection less than 1 week before recruitment.
  3. Females of childbearing potential who are pregnant, planning to get pregnant and/or breast feeding or not willing to practice an approved method of birth control.
  4. Presence of psychiatric disorder, such as schizophrenia or major depression, in the investigator's opinion, could interfere with study requirements.
  5. Patients undergoing surgery due to acute illness or hospitalized.
  6. Existence of any medical condition which, in the investigator's opinion based on anamnesis or medical records, could affect study completion, including but not limiting visual problems or cognitive deterioration.
  7. Patients currently treated or who have been treated with any other study drug or treatment within 30 days prior to baseline visit.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00400647

Basel, Switzerland
Sponsors and Collaborators
Study Director: Novartis Novartis
  More Information

Additional Information:
Responsible Party: Novartis Identifier: NCT00400647     History of Changes
Other Study ID Numbers: CERL080AES06
Study First Received: November 16, 2006
Last Updated: February 3, 2017

Keywords provided by Novartis:
kidney transplant
enteric-coated mycophenolate sodium
quality of life
gastrointestinal symptoms

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on April 24, 2017